<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349528</url>
  </required_header>
  <id_info>
    <org_study_id>SMRI/SPHS: 2017-01</org_study_id>
    <nct_id>NCT03349528</nct_id>
  </id_info>
  <brief_title>Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Bipolar Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheppard Pratt Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheppard Pratt Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if taking a probiotic supplement versus a placebo
      will reduce relapse and improve the clinical course among participants who have been
      hospitalized for bipolar depression.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Relapse</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Time to relapse defined as time until psychiatric rehospitalization during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>New Mood Episodes</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Number of new mood episodes determined by Structured Clinical Interview for DSM-5 Disorders (SCID-5), an interview using criteria from the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Psychiatric Rating Scale</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Severity of psychiatric symptoms determined by Brief Psychiatric Rating Scale (BPRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Young Mania Rating Scale</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Severity of mania-related symptoms determined by Young Mania Rating Scale (YMRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Severity of depression-related symptoms determined by Montgomery-Åsberg Depression Rating Scale (MADRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Severity of depression-related symptoms determined by Hamilton Depression Rating Scale (HAM-D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Columbia-Suicide Severity Rating Scale</measure>
    <time_frame>Weeks 0 - 24 of study participation</time_frame>
    <description>Occurrence of suicide attempts and ideation during the treatment period determined by the Columbia-Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intestinal Inflammation</measure>
    <time_frame>Baseline, Week 12, Week 24</time_frame>
    <description>Levels of immune markers related to intestinal inflammation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bipolar Depression</condition>
  <arm_group>
    <arm_group_label>Probiotic Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The probiotic supplement will consist of capsules containing approximately 1 billion (1.0 x 10^9) colony forming units of the probiotic organisms, Lactobacillus rhamnosus LGG® (LGG®) and Bifidobacterium animalis subsp. lactis BB-12® (BB-12®). The capsule, which will be swallowed, is a size 3 opaque, hard, hypromellose capsule. Participants will be asked to take 1 capsule of the probiotic supplement with a meal or with a snack daily for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inert Compound</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The inert compound placebo looks identical to the probiotic supplement, and participants will be instructed to swallow 1 capsule with a meal or with a snack daily for 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Probiotic Supplement</intervention_name>
    <description>Probiotic supplement 1 tablet by mouth daily</description>
    <arm_group_label>Probiotic Supplement</arm_group_label>
    <other_name>Probio-Tec® BG-VCap-6.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inert Compound</intervention_name>
    <description>Probiotic identical placebo 1 tablet by mouth daily</description>
    <arm_group_label>Inert Compound</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65 (inclusive)

          -  Capacity for written informed consent

          -  Currently (or within the last 3 weeks) admitted to a Sheppard Pratt inpatient or day
             hospital program for symptoms of a depressive episode and a diagnosis Bipolar Disorder
             I or II, most recent episode depressed per Diagnostic and Statistical Manual of Mental
             Disorders 5th Edition (DSM-5), the diagnosis of which is confirmed with the Structured
             Clinical Interview for DSM-5 Disorders (SCID-5)

          -  Proficient in the English language

          -  Available to come to Sheppard Pratt Towson for study visits after hospital discharge

        Exclusion Criteria:

          -  Depressive symptoms better accounted for by a diagnosis of Major Depressive Disorder,
             Schizoaffective disorder, Schizophrenia, or disorder(s) other than Bipolar Disorder I
             or II

          -  DSM-5 diagnosis of intellectual disability or comparable diagnosis determined by
             previous version of the DSM

          -  Substance- or medically-induced mood symptoms at time of Visit 1/Baseline visit

          -  DSM-5 diagnosis of a moderate or severe substance use disorder, except for caffeine or
             tobacco, within three months prior to the Visit 1/Baseline visit

          -  History of IV drug use

          -  Any clinically significant or unstable medical disorder as determined by the principal
             investigator and/or the study physician (e.g., HIV infection or other immunodeficiency
             condition, uncontrolled diabetes, congestive heart failure)

          -  A serious medical condition that affects brain or cognitive functioning (e.g.,
             epilepsy, serious head injury, concussion involving loss of consciousness, brain
             tumor, or other neurological disorder)

          -  Pregnant, planning to become pregnant, or breastfeeding during the study period

          -  Documented celiac disease

          -  Participated in any investigational drug trial in the 30 days prior to the Visit
             1/Baseline visit

          -  Receipt of Electroconvulsive therapy (ECT) in the 30 days prior to the Visit
             1/Baseline visit or planned ECT after hospital discharge
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faith Dickerson, PhD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheppart Pratt Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cassie Stallings, RNC, MA</last_name>
    <phone>410-938-3000</phone>
    <email>cstallings@sheppardpratt.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sheppart Pratt Health System</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2017</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheppard Pratt Health System</investigator_affiliation>
    <investigator_full_name>Faith Dickerson, PhD, MPH</investigator_full_name>
    <investigator_title>Principal Investigator, Stanley Research Program</investigator_title>
  </responsible_party>
  <keyword>bipolar disorder</keyword>
  <keyword>bipolar depression</keyword>
  <keyword>depressive episode</keyword>
  <keyword>probiotic supplement</keyword>
  <keyword>probiotics</keyword>
  <keyword>relapse prevention</keyword>
  <keyword>rehospitalization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

